Krystal Biotech (KRYS) Q2 FY26 earnings call: guidance and Q&A

Seeking clarity on European VYJUVEK demand despite flat reported revenue, compliance in Germany/France, and details on the Hailey-Hailey program's market, data, and registrational study plans.

Laurent Goux confirmed strong underlying demand and patient inclusion/volume growth in Europe, attributing flat revenue to German pricing reserves. Compliance is good, similar to the U.S. Suma Krishnan detailed Hailey-Hailey's natural history study, scale validation, and Phase 1 study design, expecting data to inform FDA on endpoints for a 2027 registrational study.

“the market dynamics are pretty strong. We have been -- we're facing a strong growth in both patient inclusion and volume.”

asked by Jiale Song · answered by Laurent Goux

Inquired about a previously disclosed NK patient with complete closure, its relevance to the Emerald One study, and the functional metrics expected from the 5-patient CF study.

Krish Krishnan cautioned against over-interpreting single-patient data for NK, noting it was a legal disclosure. Suma Krishnan clarified the patient had chronic wounds, showed durability, and the new study has a similar population but a different dosing regimen. For CF, the study focuses on repeat dosing safety and FEV1 measurements over 6 months in sick patients with low FEV1.

“it was a legal requirement that made us disclose that one patient data stemming from some of the patent disclosures... We have always said and expressed to not have the investment community read too much into a single patient data.”

asked by Alec Stranahan · answered by Krish Krishnan

Asked for more specifics on German vial growth versus accrual impact and clarification on the NK trial's data readout timeline (late 2026 vs. early 2027).

Laurent Goux reiterated strong patient inclusion and vial increase in Germany but did not provide specific country-by-country numbers. Krish Krishnan explained the accrual impact, expecting German negotiations to complete in Q3, with Q4 returning to actual net revenue. Suma Krishnan confirmed NK enrollment by year-end, with data likely in early 2027 due to global filing strategy and database cleaning.

“we are expecting at this moment to complete negotiations in Q3, pricing negotiations in Germany... hopefully, by the time Q4 comes around, we'll be back to an actual net revenue number in Germany.”

asked by Yigal Nochomovitz · answered by Krish Krishnan

Inquired if NK enrollment completion/data was delayed for European patients, the overall enrollment rate, and the remaining commercial opportunity for VYJUVEK in the U.S. community setting, especially for DDAB patients.

Suma Krishnan clarified that NK enrollment is not delayed but expanded globally to facilitate a single global filing, utilizing European sites to speed up recruitment without upsizing the trial. Christine Wilson stated there's still significant opportunity in the U.S. community, with DDAB patients growing, and the company has surpassed its initial 60% penetration target of diagnosed patients. Krish Krishnan added that demand remains strong with 35-50 reimbursement approvals quarterly, and the company will target the 3,000 undiagnosed patients after the initial 1,200 identified.

“we are not upsizing the study trial. It's just it we want to do global filing, we want to increase recruitment with keeping the study design the same and the number the same.”

asked by Ritu Baral · answered by Suma Krishnan

Asked about the potential impact of new German drug pricing reforms on ongoing negotiations and the status of U.S. PBM negotiations for at-home VYJUVEK administration.

Laurent Goux acknowledged evolving German reforms but stated negotiations are constructive, aiming for sustainable reimbursement reflecting clinical value and unmet need, consistent with international reference pricing. Krish Krishnan noted consistently good access in the U.S. since launch, with productive relationships with payers and no substantive issues regarding pricing or rebates, even with at-home administration.

“each market has its own pricing and reimbursement framework and specificities... our focus is definitely on achieving sustainable reimbursement that reflects Rajive clinical value.”

asked by Lachlan Hanbury-Brown · answered by Laurent Goux

Inquired about the commercial opportunity for NK, particularly regarding patients with prior corneal surgeries, and whether there's any read-through from the ocular DEB program's readout to NK.

Krish Krishnan confirmed NK is a large and growing market, with trends in claims data and OxoVit sales indicating increasing diagnoses and treatment, and a significant underserved population worldwide. Suma Krishnan clarified that ocular DEB (KB803) and NK (KB801) are mechanistically different: KB803 is prophylactic with patient-reported outcomes, while KB801 involves wound healing and physician-assessed endpoints, making direct read-through inappropriate.

“it's clear the number of patients being diagnosed and treated annually with NK has increased dramatically... Point being a large and growing market in the United States.”

asked by Debjit Chattopadhyay · answered by Krish Krishnan

Asked if the ocular DEB program includes global patients, the screening-to-enrollment rates and demand for the NK trial, and if European vial sales increased sequentially, quantifying if possible.

Suma Krishnan stated the ocular DEB study is U.S.-based due to European non-acceptance of patient-reported outcomes as endpoints. For NK, enrollment is picking up, with sites in Europe coming online to increase recruitment for a global filing. Krish Krishnan confirmed European vial sales increased sequentially in double digits but declined to quantify further to avoid perpetual tracking.

“I mean for the I study ocular. It's not a global study because I think patient-reported outcomes are not very well accepted by Europe.”

asked by Cal Patel · answered by Suma Krishnan